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Abstract
Background and Objective Omeprazole is a proton pump inhibitor that is used in acid suppression therapy in infants. Infants 
cannot swallow the oral tablets or capsules. Since, infants require a non-standard dose of omeprazole, the granules or tab-
lets are often crushed or suspended in water or sodium bicarbonate, which may destroy the enteric coating. In this study 
we explore the efficacy and pharmacokinetics of rectally administered omeprazole in infants with gastroesophageal reflux 
disease (GERD) due to esophageal atresia (EA) or congenital diaphragmatic hernia (CDH) and compare these with orally 
administered omeprazole.
Methods Infants (6–12 weeks postnatal and bodyweight > 3 kg) with EA or CDH and GERD were randomized to receive a 
single dose of 1 mg/kg omeprazole rectally or orally. The primary outcome was the percentage of infants for whom omepra-
zole was effective according to predefined criteria for 24-h intraesophageal pH. Secondary outcomes were the percentages 
of time that gastric pH was < 3 or < 4, as well as the pharmacokinetic parameters.
Results Seventeen infants, 4 with EA and 13 with CDH, were included. The proportion of infants for whom omeprazole was 
effective was 56% (5 of 9 infants) after rectal administration and 50% (4 of 8 infants) after oral administration. The total reflux 
time in minutes and percentages and the number of reflux episodes of pH < 4 decreased statistically significantly after both 
rectal and oral omeprazole administration. Rectal and oral administration of omeprazole resulted in similar serum exposure.
Conclusions A single rectal omeprazole dose (1 mg/kg) results in consistent increases in intraesophageal and gastric pH in 
infants with EA- or CDH-related GERD, similar to an oral dose. Considering the challenges with existing oral formulations, 
rectal omeprazole presents as an innovative, promising alternative for infants with pathological GERD.
Clinical Trial Register ClinicalTrials.gov Identifier: NCT00226044.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1331 8-020-00630 -8) contains 
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1 Introduction
Gastroesophageal reflux (GER) is a very common and 
self-limiting condition in infancy. If GER is accompanied 
with ‘troublesome’ symptoms or complications, such as 
esophagitis, poor weight gain, or respiratory complications, 
it is defined as gastroesophageal reflux disease (GERD) [1]. 
The incidence of GERD is estimated to be around 10% in 
healthy infants, whereas it increases to 50–90% in infants 
with birth defects, such as esophageal atresia (EA) or 
congenital diaphragmatic hernia (CDH) [2–4]. In the lat-
ter, life-threatening complications, such as aspiration or 
pneumonia, may occur. For infants with GERD who do not 
improve with conservative treatment, an empiric trial using 
acid suppression therapy with proton pump inhibitors (PPIs) 
can be considered [5, 6]. Omeprazole, a frequently used PPI, 
is commercially available in gelatin capsules or tablets con-
taining enteric-coated granules to prevent inactivation of 
omeprazole by exposure to gastric acid [7–9].
The currently available omeprazole formulations do not 
enable exact dosing in neonates and infants, as the average 
starting dose of 3 mg in a neonate (based on a recommended 
dose of 1 mg/kg/day) will be much lower than the lowest 
available solid formulation (10 mg/dose). Since infants 
cannot take solid oral formulations, these formulations are 
either crushed which damages the enteric-coated granules 
or suspended in water or sodium bicarbonate. In addition, 
infants can chew on the granules and this will also damage 
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Key Points 
A single rectal omeprazole dose results in consistent 
increases in intraesophageal and gastric pH in infants 
with gastroesophageal reflux disease due to congenital 
malformations.
A dose of 1 mg/kg rectal omeprazole in infants results in 
rapid exposure in the therapeutic range.
Rectal omeprazole presents as an innovative, promis-
ing alternative for infants with gastroesophageal reflux 
disease.
(ClinicalTrials.gov Identifier: NCT00226044). All parents 
gave written informed consent for their infant to be involved 
in the study.
2.2  Standard of care
The standard of clinical care protocol for GERD prescribed 
omeprazole 1 mg/kg with or without  Gaviscon® or domperi-
done in all infants after neonatal surgical repair for EA or 
CDH, as soon as enteral feeding was started. Between the 
age of 6 and 12 weeks postnatally, 48-h pH monitoring was 
performed to assess the severity of acid reflux and the impact 
of a single dose of omeprazole. The first 24-h pH monitoring 
was performed after the omeprazole was stopped for 4 days 
and the domperidone and  Gaviscon® (where relevant) for 
2 days. This wash-out period is a standard procedure before 
pH monitoring is performed. The omeprazole medication 
was administered as standard of care after the wash-out 
before a second 24-h pH monitoring was performed.
2.3  pH Monitoring
A portable pH meter (Orion, Medical Measurement Sys-
tems) with a two-tip measuring probe was used. The measur-
ing tips were calibrated before and after the measurement. 
The upper probe measured the pH in the esophagus and the 
lower probe measured the pH in the stomach. A chest X-ray 
confirmed the position of the two probes. The pH analysis 
was based on automated pH analysis and the measured val-
ues were compared with the Vandenplas criteria [16]. Evalu-
ation of the pH measurements was performed by trained 
gastroenterologists.
2.4  Inclusion and Exclusion Criteria
Infants were eligible for the study if they were 6–12 weeks 
postnatal, weighed > 3 kg, had undergone surgical repair for 
EA or CDH, showed clinical GERD, and were to undergo 
48-h pH measurements. Initially, all infants were randomized 
to study medication after the first 24-h pH measurement. 
After inclusion of the first 8 infants, however, only 2 fulfilled 
the criteria of GERD during the first 24-h pH measurement, 
so the protocol was changed. Only infants whose first 24-h 
pH measurement showed GERD were eligible to receive the 
study medication. Infants were excluded if they were allergic 
to omeprazole, had participated in other interventional trials, 
or had used medications known to interact with omeprazole.
2.5  Sample Size and Randomization
We planned to include 20 infants in this pilot study, with 
10 receiving omeprazole rectally and 10 orally. The pedi-
atric gastroenterologist decided if a patient was eligible for 
the coating [10, 11]. Moreover, many infants with GERD 
and an underlying disease like EA or CDH need enteral 
feeds by a gastric tube. The suspended granules are notori-
ous for causing a gastric tube blockage [9]. Finally, the com-
mercially available omeprazole suspensions are, in our opin-
ion, not a good alternative for infants because it is unclear 
if the amount of sodium bicarbonate, added to buffer the 
acid stomach content, is effective and safe in this population. 
Consequently, the oral bioavailability of currently available 
oral omeprazole formulations may be unpredictable and 
result in variable degrees of systemic drug exposure, which 
may explain the low effectiveness reported [5, 6]. In addi-
tion, the practical issues related to oral omeprazole use, e.g., 
crushing or suspending and gastric tube blockage present an 
additional burden to parents and children who are already 
overwhelmed due to the (underlying) disease.
To overcome the limitations associated with the current 
oral omeprazole formulations, alternative formulations are 
needed. Based on studies in healthy adult volunteers [12, 13] 
we developed age-appropriate omeprazole suppositories of 
good quality and stability [12–14]. In the current pilot study, 
we aimed to explore the efficacy and pharmacokinetics of 
rectally administered omeprazole in infants with GERD due 
to EA or CDH and compare these with orally administered 
omeprazole.
2  Methods
2.1  Study design
This study was an open-label randomized pilot trial to study 
the efficacy of a single orally or rectally administered 1 mg/
kg dose of omeprazole in infants with GERD due to EA or 
CDH. The study was performed at the Departments of Pedi-
atric Surgery at the Erasmus MC Sophia, Rotterdam, The 
Netherlands. The protocol was approved by the institutional 
review board of the Erasmus Medical Centre Rotterdam 
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inclusion. After inclusion, allocation was by means of the 
sealed envelope method.
2.6  Omeprazole Dose
At the start of the second day (t 24–48 h) of pH measure-
ments, the infants received a single dose of study medica-
tion—1 mg/kg of orally or rectally administered omeprazole. 
The suppositories (3–10 mg, rounded to whole milligrams) 
were prepared as described previously [12]. Uniformity of 
mass was checked and the content of uniformity as well 
as the stability were determined with a validated quantita-
tive high-performance liquid chromatography–ultraviolet 
(HPLC–UV) method. The oral suspension was also custom-
made. Briefly, commercially available 40 mg omeprazole 
capsules were opened, and the precise amount of omeprazole 
granules was measured (3–10 mg) and deposited in new cap-
sules. On the day of administration, the capsule was opened 
and the granules were dissolved in 5 ml of water. After pH 
measurements, the patients continued with the rectally or 
orally administered study omeprazole at 1 mg/kg for approx-
imately 6 weeks.
2.7  Blood Sampling for Pharmacokinetics
During the second 24-h pH monitoring, IV access was 
obtained to draw up to 10 blood samples of 1 ml (2 × 0.5 ml) 
for pharmacokinetic analysis, at the following time points—
pre-administration, and at 30, 60, 90, 120, 150 min, and 3, 
4, 6 and 8 h after omeprazole administration. The blood 
samples were centrifuged and stored in a freezer (− 80 °C) 
until the serum samples were analyzed for concentrations 
of the active drug omeprazole (OME) and the non-active 
metabolites hydroxy-omeprazole (OH-OME) and omepra-
zole-sulphone (OME-S) in the laboratory of the pharmacy 
of the Hague hospitals, using a validated HPLC with diode 
array detection method [15].
2.8  Outcomes
The primary outcome was the percentage of infants for 
whom omeprazole was effective. Efficacy was based on 24-h 
intraesophageal pH in 509 healthy infants and defined as the 
following parameters being within normal values for age 
(Supplemental Table 1)—number of episodes of pH < 4, per-
centage of time with pH < 4, number of episodes of pH < 4 
and longer than 5 min, and longest reflux episode [16]. 
The secondary outcomes were the percentage of time with 
intragastric pH > 3, the percentage of time with intragastric 
pH > 4, and analysis of the pharmacokinetic parameters.
2.9  Pharmacokinetic Analysis
The maximal concentrations of OME, OH-OME, and 
OME-S in serum (Cmax) and the time to reach Cmax (Tmax) 
were visually extracted from the serum concentration ver-
sus time curves. The area under the curve (AUC) from time 
zero to the last sampling time point (AUC 0–t) was calculated 
using the log-linear trapezoidal method. The apparent vol-
ume of distribution (Vd/F) and apparent serum clearance 
(CL/F) were calculated for OME only by using standard 
non-compartmental techniques. All pharmacokinetic param-
eters derived from individual patients were estimated using 
Excel PKsolver add-in software [17].
The criterion for excluding study patients from all phar-
macokinetic analyses was fewer than four blood samples. 
If CL/F, Vd/F, or half-life (t1/2) were not predicted because 
of non-negative estimated λz, they were excluded for the 
CL/F, Vd/F, or t1/2 analyses, respectively. If the part of AUC 
0–∞ that was extrapolated beyond the last observation was 
> 20% of the actual AUC 0–t, the AUC 0–∞ was excluded from 
the analyses, as it would introduce unreliable overestimation 
of the AUC 0–∞.
2.10  Statistical Analysis
All data were analyzed using SPSS 25. Standard descriptive 
statistics were used to describe demographic and clinical 
characteristics. Due to the small numbers and non-normal 
distributions, all continuous variables were summarized 
in medians with ranges. Differences between groups were 
analyzed using Mann–Whitney U tests, while differences in 
parameter values before and after omeprazole administration 
were analyzed using Wilcoxon Signed Ranks tests. The level 
of significance was set at p < 0.05.
3  Results
3.1  Demographics
We screened 99 infants for inclusion, of whom 65 were 
excluded for various reasons (Fig. 1). Of the 34 infants who 
underwent pH monitoring, 17 received study medication. 
The trial was terminated early for logistic and financial rea-
sons in April 2016. In total, 9 infants received omeprazole 
rectally and 8 orally. The rectal omeprazole group consisted 
of 7 boys (78%) and 2 girls (22%), whereas the gender dis-
tribution was 50%:50% in the oral omeprazole group. Birth 
weight, postnatal age at surgery, and age at pH measurement 
did not differ between the two groups (Table 1).
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3.2  Primary Outcome
3.2.1  Esophageal pH
The proportion of patients for whom omeprazole was effec-
tive, as defined above, was 56% (5 out of 9 patients) after 
rectal and 50% (4 out of 8 patients) after oral omeprazole 
(Table 2). In both groups and when dosing before and after 
were compared, the total reflux time in minutes and percent-
ages and the number of reflux episodes of pH < 4 showed a 
statistically significant decrease (p ≤ 0.015) after adminis-
tration of omeprazole (Table 2). The number of reflux epi-
sodes of pH < 4 longer than 5 min (p = 0.345) and the longest 
reflux period (p = 0.097) did not seem to decrease as much 
in the rectal omeprazole group as they did in the oral group 
(p ≤ 0.012). The patients in the rectal omeprazole group had 
better baseline values for these parameters compared to the 
oral group before omeprazole administration (e.g., longest 
median reflux periods of 4.9 vs 14.2 min, respectively). Sup-
plemental Figures 1A and 1B show the number of reflux 
episodes and the total reflux time (%) per 24 h per individual 
infant.
3.3  Secondary Outcomes
3.3.1  Gastric pH
The percentage of time with pH > 4 showed a statistically 
significant increase after both oral and rectal omeprazole 
administration (Table 2). Furthermore, the percentage of 
time with pH > 3 also showed a statistically significant 
increase (p = 0.018) after oral administration, but less so 
after rectal administration, p = 0.069 (Table 2). The patients 
in the rectal omeprazole group already had better baseline 
Fig. 1  Flow chart of screening and randomization of infants
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values for these parameters than the patients in the oral 
group.
3.4  Pharmacokinetics
From 5 infants (4 rectally and 1 orally administered omepra-
zole), blood was collected to estimate the pharmacokinetic 
parameters of omeprazole and its metabolites (Table 3). 
We were not able to collect pharmacokinetic data from all 
included infants as not all parents provided consent for the 
pharmacokinetic sub-study and in the remaining infants the 
small-bore peripheral intravenous line did not allow sam-
pling on all occasions or was not maintained throughout the 
full sampling time. The concentration time curves of OME 
and its metabolites are shown in Fig. 2a, b. The median 
(range) AUC 0–∞ was 57.7 (13.3–64.8) and 50.5 mg/L·min 
after rectal and oral dosing, respectively. The median (range) 
half-life was 65 (19–137) min after rectal and 38 min after 
oral dose administration. For rectal omeprazole, the median 
(range) Cmax was 0.3 (0.3–0.4) mg/L which was reached at 
96.5 (60–167) min. The oral Cmax was 1.0 mg/L which was 
reached at 123 min. 
3.5  Safety
No study-specific adverse events were reported during the 
study period.
Table 1  Demographic data 
of infants with oral or rectal 
administration of omeprazole
Characteristic Oral Rectal
Number of infants 8 9
Gender
 Male (n) 4 7
 Female (n) 4 2
Congenital diaphragmatic hernia (n) 6 7
Esophageal atresia (n) 2 2
Birth weight (median, range), kg 3.4 (3.0–3.8) 3.0 (2.6–4.0)
Age at surgery (median, range), day 3.5 (1.0–10.0) 4.0 (1.0–7.0)
Age at pH measurement (median, range), day 54.1 (8.1–85.3) 64.4 (2.0–99.2)
Dose per kg (median, range) mg/kg 0.98 (0.93–1.05) 1.06 (0.94–1.11)
Table 2  Efficacy of rectal and oral omeprazole
Intraesophageal and intragastric pH measurements before and after oral or rectal administration of omeprazole 1 mg/kg. Efficacy was based on 
24-h intraesophageal pH and defined as the following parameters being within normal values for age (Supplemental Table 1)—number of epi-
sodes of pH < 4, percentage of time with pH < 4, number of episodes of pH < 4 and longer than 5 min, and longest reflux episode [16]
Variable Oral (n = 8) Rectal (n = 9)
Before administration After administration p value Before administration After administration p value
Primary outcome: intraesophageal pH
 The number of reflux episodes 
of pH < 4, median (min, max)
130 (55–193) 27 (6–99) 0.012 105 (57–197) 45 (2–101) 0.008
 Total reflux time with pH < 4, 
median (min, max),  %
9.3 (3.5–37.6) 2.2 (0.1–7.0) 0.012 9.1 (2.6–15.2) 2.6 (0–9.6) 0.015
 The number of reflux episodes 
of pH < 4, > 5 min, median 
(min, max)
4 (1–28) 0.5 (0–5) 0.011 3 (0–11) 0 (0–6) 0.345
 Longest reflux period, median 
(min, max), min
14.2 (6.1–64.1) 5.6 (1.1–32.8) 0.012 4.9 (1.7–35.6) 4.5 (0.1–28.7) 0.097
Secondary outcome: intragastric pH
 Total reflux time with pH > 3, 
median (min, max),  %
54.1 (8.1–85.3) 86.3 (20.4–98.7) 0.018 64.4 (2.0–99.2) 76.9 (8.3–93.9) 0.069
 Total reflux time with pH > 4, 
median (min, max),  %
43.1 (2.9–73.6) 77.9 (15.2–95.7) 0.018 39.0 (0.8–59.2) 55.0 (3.2–82.1) 0.012
Therapeutically effective (n) 4 5
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4  Discussion
Our data show that a single rectal omeprazole dose results 
in a consistent increase in intraesophageal and intragastric 
pH in infants with congenital malformation-related GERD. 
Considering the challenges with existing oral PPI formula-
tions, rectal omeprazole presents as an innovative, promising 
alternative for infants with GERD.
Our data are in line with adult studies showing adequate 
systemic exposure and gastric acid suppression after a single 
1 mg/kg dose of rectal omeprazole [12, 13]. Our current 
data suggest that rectal omeprazole is as efficacious as oral 
omeprazole. It may be even more efficacious in regular clini-
cal care settings, as in our study the oral omeprazole could 
be more precisely dosed at approximately 1 mg/kg than in 
regular clinical care, as customized capsules were prepared. 
For regular clinical care, the smallest commercially avail-
able formulation is 10 mg, which needs to be manipulated 
by parents or care-givers to enable administration to infants, 
resulting in imprecise dosing. Hence, the efficacy of oral 
omeprazole in real-life clinical care may be more variable 
than in the current study, providing an additional rationale 
for rectal administration. Moreover, the reduction in burden 
to parents and children by reducing the logistic challenges 
of dosage form manipulations and gastric tube replacement 
often needed for tube blockage by the granules is a major 
benefit of the suppository.
Although only approximately half of the patients reached 
the primary endpoint (no GER, based on combined intrae-
sophageal pH indices), we observed that total reflux time, 
the number of reflux episodes of pH < 4, and the longest 
reflux period decreased considerably in both the oral and 
rectal omeprazol groups. Only the latter did not show a 
statistically significant decrease in the rectal group, which 
was most likely due to the already short reflux periods before 
omeprazole administration in this group. In addition, it is 
known that the maximum omeprazole effect is only reached 
after several days of administration (in adults) [18]. As we 
measured pH after a single dose only, this may explain why 
we observed large improvements in pH indices but not all 
patients reaching the primary endpoint. We would have pre-
ferred a multi-dose study, but the current study was ethically 
only feasible in the context of existing clinical care, namely 
two 24-h pH measurements on consecutive days, with and 
without omeprazole. An additional hospital visit (for ambu-
latory patients) and a second insertion of the pH probe (for 
all patients) would have been ethically unacceptable, as the 
additional burden to infants would not outweigh the poten-
tial benefit of the study. Nevertheless, we think that the data 
on a single dose of omeprazole are very informative as we 
observed a large reduction in esophageal and gastric pH. In 
a previous study in older critically ill infants (5–27 months), 
receiving approximately 0.5 mg/kg omeprazole orally, gas-
tric pH was > 4 for approximately 45% of the time, and 
in those receiving 1 mg/kg for approximately 90% of the 
time [18]. Our data are also in line with a recent dose-find-
ing study in neonates, where 24-h pH monitoring starting 
48–96 h after omeprazole initiation, supported optimal acid 
reduction at 1 mg/kg daily oral administration [19].
We were able to estimate pharmacokinetics in a sub-set of 
patients. In the four patients receiving rectal omeprazole, the 
median (range) Tmax of 97 (60–167) min was in line with the 
adults study by Choi et al. (mean ± SE Tmax 129 ± 20 min) 
[12]. In addition, the Tmax of oral omeprazole (123 min) from 
the one patient with pharmacokinetic data was also in the 
range as reported for adults and children aged 1–18 years 
Table 3  Pharmacokinetic parameters after oral and rectal administration of omeprazole 1 mg/kg
Results for rectal administration are presented as median (range)
AUC 0–t area under the serum concentration–time curve from time zero to the last sampling time point, AUC 0–∞ AUC from time 0 to infinity, 
CL/F apparent serum clearance, Vd/F apparent volume of distribution, Cmax maximum serum concentration, Tmax time to reach Cmax, NA not 
available
a For 1 patient, the part of the AUC 0–∞ that was extrapolated beyond the last observation was > 20% of the actual AUC 0–t
b For 4 patients the part of the AUC 0–∞ that was extrapolated beyond the last observation was > 20% of the actual AUC 0–t
c For 2 patients, only 1 blood sample was taken after the Cmax and Tmax of omeprazole-sulphone, hence the T0.5 could not be estimated
Parameter Omeprazole OH-omeprazole Omeprazole-sulphone
Rectal (n = 4) Oral (n = 1) Rectal (n = 4) Oral (n = 1) Rectal (n = 4) Oral (n = 1)
AUC 0–t (mg/L·min) 57.4 (13.1–79.8) 49.8 63.9 (15.7–107.6) 69.3 11.53 (2.1–27.5) 14.9
AUC 0–∞ (mg/L·min) 57.7 (13.3–64.8) (n = 3)a 50.5 68.22 (18.5–114.3) 73.6 NAb NAa
CL/F (L/min/kg) 0.016 (0.009–0.08) 0.020
Vd/F (L/kg) 2.0 (0.9–2.1) 1.2
T0.5 (min) 65.2 (18.7–137.6) 38.5 63.8 (42.4–83.0) 58.4 116.8 (77.3–156.3) (n = 2)c 118.2
Cmax (mg/L) 0.3 (0.3–0.4) 1.0 0.4 (0.2–0.7) 0.7 0.05 (0.02–0.1) 0.1
Tmax (min) 96.5 (60–167) 123 75.5 (60–167) 123 209.5 (60–247) 123
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(Tmax 60–360 h) [18, 20]. Elimination half-life was similar 
in our patients after rectal and oral administration compared 
to the study by Andersson et al. in a cohort of children aged 
1–6 years [20]. Interestingly, Choi et al. showed similar 
pharmacokinetics for rectal and oral omeprazole in adults, 
with less inter-individual variation after rectal administration 
[12]. To the best of our knowledge, oral pharmacokinetic 
data from the infant population (term infants, 1–12 months 
of age) are lacking so far. Individual pharmacokinetics are 
also of great importance. For example, one of the infants 
in this study no longer had an active omeprazole level after 
100 min. In this infant, omeprazole was not effective at all. 
Moreover, another patient showed very high metabolite lev-
els. The interplay of age and genotype on CYP2C19 activity, 
the main drug metabolizing enzyme involved in omeprazole 
disposition, may have contributed to these observations [21].
Our study had some limitations. First, this was only a 
small pilot study, with 17 patients and 5 patients with pH and 
pharmacokinetic data, respectively. The small sample size of 
this pilot study did not allow testing the superiority of rectal 
over oral omeprazole in infants and likely also explains the 
difference in baseline values between the groups. Although 
Fig. 2  Serum concentration profiles of omeprazole (OME), hydroxy-omeprazole (OH-OME) and omeprazole sulphone (OME-S) after adminis-
tration of rectal omeprazole 1 mg/kg in 4 patients (a) and oral omeprazole 1 mg/kg in 1 patient (b)
642 P. Bestebreurtje et al.
we planned to study the clinical GERD symptoms in addi-
tion to the effect of omeprazole in pH measurements of 
reflux, we were not able to collect these data reliably from 
the parents.
Therefore, although our data suggest that rectal ome-
prazole could provide an innovative and feasible option to 
reduce gastric pH in infants with GERD, further studies are 
needed to show the benefits on clinical outcomes.
To show the superiority of rectal versus oral omeprazole 
with our pH measurement-based endpoint in a randomized 
controlled trial, 521 patients per arm are needed, assuming 
56% versus 40% success percentages in the rectal versus 
oral groups, 90% power and 5% significance level. However, 
such a large study appears unfeasible. Studies focusing on 
patient-reported outcomes, which should include not only 
symptom reduction but also reduction of experienced burden 
and benefit of administration-related issues of the oral and 
rectal formulations, might be more feasible and clinically 
relevant. Finally, our study ran into several logistic chal-
lenges, leading to prolonged inclusion with financial hurdles 
and changing clinical care.
Although this was a single-center pilot study, we believe 
our results can be useful for other settings, as the manufac-
turing of the omeprazole suppositories does not require spe-
cialized equipment or expertise and can be carried out in any 
GMP-certified laboratory [12]. Moreover, the pH measure-
ments were performed according to international standards. 
In the current guidelines for GERD in the general pediatric 
population and in infants with EA and CDH, a place in the 
treatment with PPIs certainly remains for selected patients 
[22, 23]. A potential roadblock could be the acceptability 
of rectal drug administration, which varies across countries 
and appears culturally and socially determined. In countries 
where rectal paracetamol is widely used, omeprazole sup-
positories will likely be easily accepted, especially to over-
come the challenges with oral administration of omeprazole 
and other oral PPI formulations.
5  Conclusions
The incidence of GERD is between 50 and 90% in infants 
with birth defects, such as EA and CDH. As infants require 
a non-standard dose of omeprazole, the oral bioavailability 
may be unpredictable and result in variable degrees of drug 
exposure. A single rectal omeprazole dose of 1 mg/kg results 
in rapid exposure in the therapeutic range and a consistent 
increase in intraesophageal and gastric pH in infants with 
EA or CDH. We consider rectal omeprazole to be an inno-
vative, promising alternative for infants with pathological 
GERD since the results of our pilot study showed its effec-
tiveness. Further clinical studies are needed to confirm our 
results.
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